Teva Pharmaceutical Industries Ltd (TEVA) - Product Pipeline Analysis, 2021 Update
Teva drug shows promise in movement disorder - PMLiVE
Teva Pharmaceuticals and IBM Expand Global Partnership to Enable Drug Development and Chronic Disease Management with
Teva's Huntington drug launch on hold after FDA rejection | Fierce Biotech
EX-99.1
Teva and Nuvelution partner on Tourette drug development
FDA's Call on Migraine Drug Could Be Trouble for Teva | Barron's
EX-99.1
Teva: We Believe In Biosimilars, But Pipeline And Timing Come First :: Generics Bulletin
Generic Drugs in the Pipeline: 2017 Update
EX-99.1
Teva: Definitely Undervalued (NYSE:TEVA) | Seeking Alpha
Teva Announces FDA Approval of AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, a New Once-Daily Formulation of AUSTEDO® (deutetrabenazine) Tablets
TEVA | Market Realist
A Look at Teva's Generic Drugs Research Pipeline
Teva Announces FDA Approval of First and Only Digital Inhaler with Built-In Sensors – ProAir® Digihaler™ | SnackSafely.com
Plant issues plague Celltrion and Teva as FDA issues two biosimilars CRLs
Teva Pharmaceuticals Near 20-Year Lows (NYSE:TEVA) | Seeking Alpha
dough on Twitter: "@JohnCFierce $ACAD potential interested parties in $ACAD $BIIB $TEVA $AGN $PFE. IMHO I think it's $LLY https://t.co/QM6XZkoGwJ" / Twitter
Teva's (TEVA) NDA for Schizophrenia Drug Gets FDA Acceptance
Sosei see Teva pipeline cull as an opportunity | pharmaphorum
Refreshing the biologic pipeline 2020 | Nature Biotechnology
Meet The New Teva: 8% Global Generics Share, 300 ANDAs, 1,500 Launches :: Scrip
Teva, chasing Amgen's Aimovig, scores much-needed FDA approval for migraine drug Ajovy | Fierce Pharma
FDA accepts Teva-MedinCell's new drug application for schizophrenia drug
Teva Announces FDA Approval of AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, a New Once-Daily Formulation of AUSTEDO® (deutetrabenazine) Tablets | Business Wire
